ES2575995T3 - Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal - Google Patents

Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal Download PDF

Info

Publication number
ES2575995T3
ES2575995T3 ES11815379.0T ES11815379T ES2575995T3 ES 2575995 T3 ES2575995 T3 ES 2575995T3 ES 11815379 T ES11815379 T ES 11815379T ES 2575995 T3 ES2575995 T3 ES 2575995T3
Authority
ES
Spain
Prior art keywords
amino
hydroxyethoxy
carboxamide
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11815379.0T
Other languages
English (en)
Inventor
Mark A. Smith
Michael Snape
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Application granted granted Critical
Publication of ES2575995T3 publication Critical patent/ES2575995T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compuestos inhibidores de ERK en solitario o en combinación que evitan anomalías en la conectividad neuronal; o una sal farmacéuticamente aceptable y/o uno o más estereoisómeros de los mismos; para su uso en el tratamiento de síndrome del cromosoma X frágil o trastornos del espectro autista asociados a anomalías de ERK, en los que el inhibidor de ERK se selecciona entre el grupo que consiste en 2-(2-amino-3- metoxifenil)-4H-cromen-4-ona, (2Z,3Z)-bis{amino[(2-aminofenil)sulfanil]metilideno}butanodinitrilo, 5-[(4-bromo-2- clorofenil)amino]-4-fluoro-N-(2-hidroxietoxi)-1-metil-1H-bencimidazol-6-carboxamida, 2-[(2-fluoro-4-yodofenil)amino]- N-(2-hidroxietoxi)-1,5-dimetil-6-oxo-1,6-dihidropiridin-3-carboxamida, 2-(4-cloro-2-fluoro-anilino)-N-(2-hidroxietoxi)- 1,5-dimetil-6-oxo-piridin-3-carboxamida, 2-[(2-cloro-4-yodofenil)amino]-N-(ciclopropilmetoxi)-3,4-difluorobenzamida, (3R,4R)-4-(3,4-Dimetoxibencil)-3-(4-hidroxi-3-metoxibencil)dihidrofuran-2(3H)-ona, (2Z)-3-amino-3-[(4- aminofenil)sulfanil]-2-[2-(trifluorometil)fenil]prop-2-enenitrilo, hipericina, 3-(3-amino-2H-pirazolo[3,4-c]piridazin-5-il)-2- fenil-3H-pirazolo[ 1,5-a]piridin-8-io, y ácido 2-cloro-4-{[2-{[(2R)-1-hidroxi-3-metilbutan-2-il]amino}-9-(propan-2-il)-9Hpurin- 6-il]amino}benzoico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
Análisis estadístico
Los datos se analizaron por análisis de varianza (ANOVA) seguido de comparaciones post-hoc con pruebas de Fisher cuando fue apropiado. Un efecto se consideró significativo si p < 0,05. Los datos se presentan como la media  error estándar de la media.
RESULTADOS
Latencia de convulsiones
Los efectos de MPEP y alcohol perílico sobre la latencia de aparición de convulsiones se muestran en la figura 6. El análisis ANOVA descubrió un efecto del tratamiento significativo. Un análisis post hoc mostró que MPEP y alcohol perílico (25 y 50 mg/kg) aumentaron la latencia de convulsiones en comparación con el vehículo respectivo.
Latencia del paro respiratorio
Los efectos de MPEP y alcohol perílico sobre la latencia del paro respiratorio (y posterior muerte) se muestran en la figura 7. El análisis ANOVA descubrió un efecto del tratamiento significativo. El análisis post hoc descubrió que MPEP y alcohol perílico (25 y 50 mg/kg) prolongaron significativamente la latencia del paro respiratorio en comparación con el vehículo respectivo. Los ratones tratados con MPEP (30 mg/kg) no mostraron dificultad respiratoria durante los ensayos y, por lo tanto, a todos se les dio una latencia de 240 s.
Escala de convulsiones media
Los efectos de MPEP y alcohol perílico sobre la escala de convulsiones media se muestran en la figura 8. El análisis ANOVA descubrió un efecto del tratamiento significativo. Un análisis post hoc mostró que, en comparación con el vehículo, MPEP y alcohol perílico (25 y 50 mg/kg) redujeron significativamente la escala de convulsiones.
16

Claims (1)

  1. imagen1
ES11815379.0T 2010-08-05 2011-08-05 Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal Active ES2575995T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37085410P 2010-08-05 2010-08-05
US370854P 2010-08-05
US40536910P 2010-10-21 2010-10-21
US405369P 2010-10-21
PCT/US2011/046773 WO2012019113A2 (en) 2010-08-05 2011-08-05 Inhibitors of erk for developmental disorders of neuronal connectivity

Publications (1)

Publication Number Publication Date
ES2575995T3 true ES2575995T3 (es) 2016-07-04

Family

ID=45560094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11815379.0T Active ES2575995T3 (es) 2010-08-05 2011-08-05 Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal

Country Status (8)

Country Link
US (1) US20150141380A1 (es)
EP (1) EP2600862B1 (es)
KR (1) KR20130113430A (es)
CN (1) CN103221043B (es)
AU (1) AU2011285611B2 (es)
CA (1) CA2807510A1 (es)
ES (1) ES2575995T3 (es)
WO (1) WO2012019113A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835513B2 (en) * 2013-06-28 2020-11-17 The Regents Of The University Of California Methods and treatments for the learning and memory deficits associated with Noonan syndrome
CN108024990B (zh) * 2015-08-31 2020-08-11 深圳青雅启瑞生物科技有限公司 美金刚与牛蒡子苷元的缀合物及其组合物和用途
LT3697405T (lt) * 2017-10-17 2021-10-25 Atriva Therapeutics Gmbh Naujas mek inhibitorius virusinėms ir bakterinėms infekcijoms gydyti
CA3096759A1 (en) * 2018-04-13 2019-10-17 Healx Limited Kit, composition and combination therapy for fragile x syndrome
IL264854A (en) 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
WO2023196412A1 (en) * 2022-04-06 2023-10-12 Nobias Therapeutics, Inc. Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
US6150401A (en) 1998-01-06 2000-11-21 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
IT1299195B1 (it) 1998-06-25 2000-02-29 Sigma Tau Healthscience Spa Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
US6147107A (en) 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6696440B1 (en) 1999-01-07 2004-02-24 Warner-Lambert Company Treatment of asthma with MEK inhibitors
US6063383A (en) 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2002002097A2 (en) * 2000-06-30 2002-01-10 Sweatt J David Methods for treating seizure disorders by inhibiting mapk pathway activation with nitriles
AU2001290940A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2003039536A1 (en) 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
EP1472206A1 (en) 2002-02-05 2004-11-03 Hormos Medical Corporation Lignan derivatives
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TW200520745A (en) * 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TWI361066B (en) * 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
WO2006134469A1 (en) * 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2461682A4 (en) * 2009-08-03 2013-03-06 Theta Biomedical Consulting & Dev Co Inc METHOD FOR TREATING AUTISTICAL DISEASES AND COMPOSITIONS THEREFOR

Also Published As

Publication number Publication date
EP2600862A2 (en) 2013-06-12
EP2600862A4 (en) 2014-01-22
EP2600862B1 (en) 2016-04-20
AU2011285611B2 (en) 2014-10-02
WO2012019113A2 (en) 2012-02-09
US20150141380A1 (en) 2015-05-21
AU2011285611A1 (en) 2013-03-14
KR20130113430A (ko) 2013-10-15
WO2012019113A3 (en) 2012-08-09
CN103221043A (zh) 2013-07-24
CN103221043B (zh) 2016-04-06
CA2807510A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
ES2575995T3 (es) Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
US9975852B2 (en) Quinoline sulfonyl derivatives and uses thereof
CL2008003326A1 (es) Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras.
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CO6390038A2 (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
NO20083033L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
AR053569A1 (es) Derivados de pirazol
MA31358B1 (fr) Méthodes de traitement du cancer à l&#39;aide d&#39;inhibiteurs de pi3k alpha à base de pyridopyrimidinone
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
UY32695A (es) FORMA DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL DE UN INHIBIDOR DE LA FAMILIA Bcl-2
CO6231036A2 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
SMT201300096B (it) Inibitori di prolil idrossilasi
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
ECSP055867A (es) Derivados de pirrolopirimidina
UY30906A1 (es) Productos farmaceuticos comprendiendo primer ingrediente activo n-[2-(dietilamino)-n-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benziotazol-7-il)etil)-3-[2-(1-nafti)etoxi]propanamida o una sal y un segundo seleccionado de un grupo especifico
CL2012001449A1 (es) Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.